StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Stock analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Several other research firms have also recently issued reports on VNRX. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of VolitionRx in a report on Monday, March 31st. HC Wainwright assumed coverage on shares of VolitionRx in a research report on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, VolitionRx currently has a consensus rating of “Hold” and an average target price of $3.33.

VolitionRx Stock Down 5.1 %

NYSE VNRX opened at $0.48 on Tuesday. The stock has a market capitalization of $48.37 million, a P/E ratio of -1.33 and a beta of 1.15. VolitionRx has a 52-week low of $0.42 and a 52-week high of $0.91. The firm has a 50-day moving average price of $0.54 and a 200 day moving average price of $0.61.

Insiders Place Their Bets

In other VolitionRx news, CEO Cameron John Reynolds purchased 181,818 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 12.80% of the stock is currently owned by company insiders.

Institutional Trading of VolitionRx

Several large investors have recently modified their holdings of VNRX. Geode Capital Management LLC boosted its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in VolitionRx during the fourth quarter worth approximately $29,000. Northern Trust Corp boosted its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the last quarter. Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in VolitionRx during the fourth quarter worth approximately $36,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.